


HALF-YEAR REPORT AS OF JUNE 30, 2010

Clopidogrel recall weighs on otherwise good business performance

- ▶ Top-performing part of business is the Operating Segment Parenteral with double-digit revenue growth
- ▶ Impact of clopidogrel recall on EBIT of EUR 14.5 million leading to a net loss of EUR 2.7 million in the first half-year 2010
- ▶ Excluding recall-related exceptional items: total revenue at last year's level – strong EBITDA-margin of 30% – net profit of EUR 8.6 million
- ▶ Strengthened marketing initiatives broaden geographic presence
- ▶ Good progress of development pipeline
- ▶ Outlook 2010: positive sales development in the second half-year expected



ACINO | FIRST HALF-YEAR 2010 AT A GLANCE

Basle, July 29, 2010. 07.00h. – The recall of clopidogrel in the period under review caused the first half-year 2010 to close with a net loss of EUR 2.7 million (column [1] in table below). Even an otherwise solid performance and double-digit growth of the Operating Segment Parenteral could not fully compensate the negative exceptional effects associated with one of Acino's major products. Excluding those exceptional items, Acino has reached last year's revenue level and has maintained its EBITDA-margin at 30%. Net profit excluding exceptional items amounted to EUR 8.6 million (column [2]).

Key figures Acino Group

(in EUR million)	<u>1.1. – 30.6.10</u>	
	[1]	[2]
Revenue	61.6	73.6
<i>thereof Peroral</i>	42.1	54.1
<i>thereof Parenteral</i>	19.5	19.5
EBITDA	7.4	21.9
<i>in % revenue</i>	12%	30%
Operating (loss) / profit; EBIT	(5.6)	8.9
<i>in % revenue</i>	(9%)	12%
Net (loss) / profit before tax	(3.6)	10.9
Net (loss) / profit	(2.7)	8.6
<i>in % revenue</i>	(4%)	12%
Equity (as of 30.6.)	246.8	
Cash flow from operating activities	12.9	
Investment in property, plant, and equipment	6.7	
Investment in intangible assets	3.8	
Headcount (full-time basis)	426	

[1] Consolidated financial results first half-year 2010

[2] Pro forma financials excluding exceptional items directly resulting from the recall

▶ **Clopidogrel recall weighs on otherwise good business performance**

The unexpected and in Acino's judgment unnecessary recall of certain clopidogrel batches entailed exceptional charges and significantly impacted the company's performance in the first half-year 2010. Excluding these effects, sales and margins reached satisfactory levels in the first six months of 2010 amidst fierce pricing competition in the markets.

Revenues in the reporting period amounted to EUR 61.6 million (excluding recall-related items EUR 73.6 million; H1-09: EUR 73.7 million). Operating expenditure – including goods and services purchased and other operating expenses – increased slightly since the second quarter revenue was based on higher product volumes. The increase in employee benefits can be attributed to the strengthening of the Swiss franc which is the currency most relevant for salary payments.

The Group generated a half-year EBITDA of EUR 7.4 million (excluding recall-related items EUR 21.9 million; H1-09: EUR 24.4 million). On an adjusted basis, this corresponds to an operating margin of 30% and reflects a slight margin erosion of three basis points (year-on-year) as a consequence of price concessions in a highly competitive generics market. With depreciation and amortization at the expected level, EBIT declined to EUR minus 5.6 million (excluding recall-related items positive EUR 8.9 million; H1-09: EUR 13.0 million). The financial result was positively influenced by gains on the cash held in CHF and revalued at the period-end foreign exchange-rate of EUR/CHF 1.33. Income tax was slightly lower than expected due to an adjustment of current income tax related to previous years. Overall, this added up to a net loss of EUR 2.7 million (excluding exceptional recall-related items net profit of EUR 8.6 million; H1-09: EUR 11.3 million).

ACINO | FIRST HALF-YEAR 2010 AT A GLANCE

Cash-flow was negatively impacted by a large increase of trade receivables. This was mainly due to payments for clopidogrel deliveries being withheld by our customers until a settlement agreement can be reached. Nevertheless, Acino generated a free cash flow of EUR 1.7 million in the first half-year 2010 (H1-09: EUR 4.0 million). After dividend payments, this resulted in a net cash reduction of EUR 2.7 million (H1-09: reduction EUR 3.5 million). Hence all investments in property, plant and equipment in the amount of EUR 6.7 million (H1-09: EUR 11.3 million) and in intangible assets (mainly development projects for new products) of EUR 3.8 million (H1-09: EUR 5.7 million) were financed from own resources. Acino's balance-sheet remains free of debt with an equity-ratio of 73% (H1-09: 73%) and cash of EUR 29.9 million.

► Clopidogrel

Operations are back on track with the swift replacement of certain recalled clopidogrel batches using active ingredient (API) from two alternative sources. Owing to sufficient drug supplies and an accelerated formulation throughput (i.e. compression of active ingredient into tablets) at the manufacturing site Liesberg, Acino was able to supply finished product without interruption.

The full financial impact of the European recall is still difficult to assess as it is presently not completely finalized. Acino has made a provision over EUR 12.0 million that should cover the impact on sales once the goods in question will be returned from and credited to the customers. Acino is invoicing ongoing deliveries of clopidogrel to its customers at contract prices and recorded sales in line with its accounting policies.

The inventory value of active ingredient and finished goods was adjusted by EUR 2.3 million and exceptional costs directly related to the recall amounted to EUR 0.2 million up to the end of June.

Since the recall procedure is not completed, the allocation of these and additional recall costs to the involved parties, including the active ingredient manufacturer and the insurance, is not yet settled. The book values of the intangible assets for clopidogrel and the goodwill for the Operating Segment Peroral have been reviewed by management and an impairment was deemed unnecessary.

To date, Acino is in discussions with the API supplier Glochem concerning compensation payments. Acino also filed an objection against the temporary suspension of marketing authorization of the product subject to the recall.

In Germany, new drug rebate agreements were reached between insurers and pharmaceutical companies. The price development in the German market is such that many commodity generic products see a fast price decline once they are being included in discount contracts with sick funds like AOK. Clopidogrel is in this context no exception. Acino took the strategic decision not to offer prices which do not provide a minimum level of profit. Going for market share is not a sound strategy in Germany since consumer (sick fund) loyalty is non-existent. As a result the company and its marketing partners did not manage to secure the AOK contracts (for a two-year period) for clopidogrel. At the same time, however, Acino's customer have been successful in securing contracts with other sick funds.

Whereas the company will lose market share in the German market as a result of not winning the AOK tender and the decision of one of its customers to switch to his own in-house product. Acino still sees substantial growth potential in markets like Italy, Spain and France, where the generic penetration of clopidogrel is still very low but expected to increase going forward. On this basis, it is Acino's target to achieve current year unit sales at almost the level of 2009.

ACINO | FIRST HALF-YEAR 2010 AT A GLANCE

▶ Operating Segment Peroral: own product portfolio developing positively

Overall sales of the **Operating Segment Peroral** (solid oral dosage forms) decreased in the first half-year by 26% year-on-year and reached EUR 42.1 million (excluding recall-related items EUR 54.1 million; H1-09: EUR 57.0 million).

Good revenue was recorded for several peroral products from own development, but growth was mainly driven by the antihypertensive metoprolol succinate, which is launched in most European markets. Demand for the analgesic oxycodone is expected to further increase after conclusion of the current health insurance rebate round in Germany. In addition to the negative impact from the product recall, sales of clopidogrel were also affected by price decreases given the heightened generic competition and lower prices in the newly launched markets outside Germany.

In an effort to optimize the product mix and to secure sufficient capacities for higher margin products from own development, revenue from contract manufacturing in Liesberg has further decreased.

▶ Strong double-digit growth of the Operating Segment Parenteral

A dynamic sales growth of 17% year-on-year reflected the strong performance of the **Operating Segment Parenteral** (transdermal therapeutic systems and biodegradable drug implants). Sales in the first six months 2010 amounted to EUR 19.5 million (H1-09: EUR 16.7 million).

On the back of the AOK contracts won for fentanyl, high order intake for this key product was the primary contributor to the buoyant and robust sales development. In volume, the increase even amounted to 39% year-on-year; the contribution margin slipped slightly to 31% (H1-09: 37%).

▶ Marketing & Distribution

Geographically, the marketing activities were further broadened in line with Acino's emphasis on geographic diversification and to reduce the exposure to the German market.

New out-licensing contracts were closed for several products in the launch phase. One example is Goserelin for which a marketing agreement covering all of Europe was concluded with one of the world's large generic pharmaceutical company.

Acino's fentanyl patch was successfully licensed out to an US partner.

In Emerging Markets, the growing middle classes have a clear demand for high quality (and, as a result, higher priced) Swiss/German made pharmaceuticals and in many cases pay their medicines out of their own pocket. Hence, as an important part of the de-risking strategy, first initiatives were started to tap the market potential in selected emerging markets. First success was seen in the Middle East and, with newly established presence in Asia, expectations are that Acino will start to see contributions of this new strategy to overall company performance already in 2011.

▶ Own development Projects

Acino's development pipeline focuses on technologically challenging generics with formulation benefits, based on its advanced technology platforms.

At the moment, Acino has 19 own projects in development, i.e. seven solid oral forms (thereof one in registration), seven transdermal systems, four biodegradable implants (thereof three in registration) and one new chemical entity (the antibiotic Iclaprim), and 15 potential projects are in early evaluation.

Approval for the **oral capsule project in registration** is still expected in the current year with a first launch at the end of this or the beginning of next

ACINO | FIRST HALF-YEAR 2010 AT A GLANCE

year. Annual sales are estimated in the mid single-digit million EUR range.

The **goserelin 3-month implant** has been approved in Switzerland. The Swiss approval also serves as a basis for submissions with customers in various countries outside of Europe. Approval in Europe itself is expected during first quarter 2011.

The registration process for the **leuprorelin 1 and 3-month implants** is on track and approval for Europe is expected before mid of next year.

Clinical studies with the **new fentanyl patch** based on an innovative formulation have been successfully completed. The low load of active substance combined with a high depletion during the treatment period makes this product very attractive. The reduced potential for opioid abuse due to the minimal drug amount is a unique selling point. Besides progressing with its own development, Acino has transferred the technology to a US license partner for further development and submission of the product to the US FDA.

Another **transdermal project**, for which a phase I pilot study has already been successfully completed, will be submitted to the FDA in the US during next year.

For **buprenorphine**, extensions to the currently marketed 3-day patch are in development and will further strengthen Acino's leading role in transdermal opioid delivery.

The antibiotic compound **iclaprim**, which had been acquired from former Arpida, has been reassessed with input from well-recognized international key opinion leaders. New aspects together with the growing need for new antibiotics could strongly increase the interest in this compound. The potential strategy for completion of development and registration will be discussed with the FDA by the end of this year.

▶▶ Customer Projects

In addition to its own development pipeline, Acino has various customer projects in clinical development, the most advanced being a novel contraception patch.

The project for a new contraceptive patch on behalf of Bayer Schering Pharma is on track. At present, the phase III program for this small and low dosed patch containing a combination of ethinyl-estradiol and gestoden is advancing. Acino, who aims at supplying Bayer Schering Pharma with the novel patches, has initiated the necessary capacity expansion at its Miesbach site to satisfy the expected demand. After fentanyl and buprenorphine, the contraceptive product will be the third matrix patch on the market that uses Acino's advanced technology.

▶▶ Evaluation Projects

Several potential projects to be developed as **oral dispersible films (ODF)** are in evaluation. The ODF technology platform has been newly established within Acino. ODFs are thin films which dissolve quickly in the mouth. They allow convenient oral administration of medicines even without water, and they may achieve a quicker onset of action compared to a tablet. Hence, ODFs are beneficial for example for the treatment of young children or elderly as well as in certain diseases.

In the collaboration with Polyphor, the feasibility of specific delivery technologies from Acino for Polyphor's innovative **PEM** molecules (Protein Epitope Mimetics) has been successfully proven.

▶▶ Outlook 2010

In 2010, excluding the direct financial impact of returned goods following the clopidogrel recall, Acino expects to generate revenues in the order of the prior year. A positive sales development in the second half of 2010 will be instrumental to reach this

ACINO | FIRST HALF-YEAR 2010 AT A GLANCE

goal. On the earnings side, management views an EBITDA-margin of 25% as a sustainable profitability level going forward.

Proactive initiatives such as efforts to expand the customer base and taking the Acino portfolio to new geographies have started to bear fruit. The acceleration of these activities will further strengthen the revenue stream and reduce the dependence on the German market

Acino has over the last years established a strong reputation as a quality manufacturer of complex and difficult to make pharmaceuticals. Based on this reputation, the company strengthened its efforts to proactively offer its formulation technologies and know-how to research-driven pharmaceutical companies. This has opened the door to a variety of interesting development projects which may lead to more sustainable revenue streams in the longer term.

ACINO | FINANCIAL REPORT
Consolidated Income Statement (condensed, unaudited)

in EUR 1 000

	1.1.-30.6.10	1.1.-30.6.09
Revenue	61 570	73 650
- thereof Operating Segment Peroral	42 086	57 005
- thereof Operating Segment Parenteral	19 484	16 645
Change in inventories	(578)	(461)
Work performed by the entity and capitalized	1 793	2 025
Goods and services purchased	(27 340)	(26 115)
Employee benefits	(16 831)	(15 379)
Other operating expenses	(11 468)	(9 486)
Other operating income	265	140
Operating profit before depreciation, amortization, net financial result and taxes (EBITDA)	7 411	24 374
<i>in % revenue</i>	12.0%	33.1%
Depreciation	(3 576)	(2 694)
Operating profit before amortization, net financial result and taxes (EBITA)	3 835	21 680
<i>in % revenue</i>	6.2%	29.4%
Amortization	(9 438)	(8 688)
Operating (loss) / profit (EBIT)	(5 603)	12 992
<i>in % revenue</i>	(9.1%)	17.6%
Financial result	1 307	1 261
Result from associated companies	669	354
Net (loss) / profit before tax	(3 627)	14 607
Income tax	897	(3 306)
Net (loss) / profit *	(2 730)	11 301
<i>in % revenue</i>	(4.4%)	15.3%
Earnings per share in EUR		
- undiluted	(0.86)	3.56
- diluted	(0.86)	3.55

Consolidated Statement of Comprehensive Income (condensed, unaudited)

in EUR 1 000

	1.1.-30.6.10	1.1.-30.6.09
Recognized amounts for pension schemes taken directly to equity	1 353	240
Tax effects	(216)	(58)
Net effect of currency translations	-	(5 208)
Other comprehensive income	(1 137)	(5 026)
Net (loss) / profit	(2 730)	11 301
Total comprehensive (expense) / income *	(3 867)	6 275

* fully attributable to the shareholders of Acino Holding Ltd.

ACINO | FINANCIAL REPORT
Consolidated Balance Sheet (condensed, unaudited)

In EUR 1 000	30.6.10	31.12.09	1.1.09*
Assets			
Property, plant and equipment	85 363	82 363	68 515
Goodwill	70 992	70 992	71 150
Other Intangible assets	83 734	89 343	96 362
Financial investments	3 712	2 574	2 487
Other non-current assets	3 859	4 000	3 894
Total non-current assets	247 660	249 272	242 408
Inventories and work in progress	22 081	20 903	23 823
Trade receivables	33 268	20 363	16 117
Other current assets	7 000	6 190	10 067
Cash and cash equivalents	29 868	32 584	17 529
Total current assets	92 217	80 040	67 536
Total assets	339 877	329 312	309 944
Liabilities and shareholders' equity			
Total shareholders' equity	246 815	256 018	226 287
Non-current financial liabilities	-	-	2 516
Deferred tax liabilities	20 623	22 878	27 883
Other non-current financial liabilities	12 493	13 429	16 015
Total non-current liabilities	33 116	36 307	46 414
Current financial liabilities	-	566	350
Deferred revenue, current portion	20 890	12 661	12 679
Other current liabilities	39 056	23 760	24 214
Total current liabilities	59 946	36 987	37 243
Total liabilities	93 062	73 294	83 657
Total liabilities and shareholders' equity	339 877	329 312	309 944

* Opening balance sheet in EUR, as the reporting currency has been changed from CHF to EUR.

ACINO | FINANCIAL REPORT
Consolidated Cash Flow Statement (condensed, unaudited)

in EUR 1 000

	1.1.-30.6.10	1.1.-30.6.09
Net (loss) / profit	(2 730)	11 301
Adjustments for non-cash items	27 495	13 745
Depreciation & amortization	13 014	11 381
Change in deferred taxes	(2 001)	(344)
Change in deferred revenue	7 294	1 670
Change in provisions and other non-current liabilities	11 157	581
Other	(1 969)	457
Cash flow from operating activities before changes in working capital	24 765	25 046
Changes in working capital	(11 836)	(4 158)
Cash flow from operating activities	12 929	20 888
Investment in property, plant and equipment	(7 407)	(11 251)
Investment in intangible assets	(3 829)	(5 644)
Purchase price repayment of / acquisition of subsidiaries	-	4 831
Other cash flow from investing activities	-	(10)
Cash flow from investing activities	(11 236)	(12 074)
Cash flow from financing activities	(4 703)	(4 613)
Effect of current exchange rate fluctuations on liquid funds	294	(750)
Net change in cash	(2 716)	(3 451)

Consolidated Statement of Changes in Equity (condensed, unaudited)

in EUR 1 000

	Share capital	Share premium	Treasury shares	Reserves	Total
Balance as of January 1, 2009	823	16 315	(3 094)	212 243	226 287
Total comprehensive income	-	-	-	6 275	6 275
Change in treasury shares	-	-	1 096	(212)	884
Employee stock plan	-	-	-	503	503
Dividends	-	-	-	(5 291)	(5 291)
Balance as of June 30, 2009	823	16 315	(1 998)	213 518	228 658
Balance as of January 1, 2010	823	16 315	(2 355)	241 235	256 018
Total comprehensive (expense) / income	-	-	-	(3 867)	(3 867)
Change in treasury shares	-	-	356	330	686
Employee stock plan	-	-	-	(457)	(457)
Dividends	-	-	-	(5 565)	(5 565)
Balance as of June 30, 2010	823	16 315	(1 999)	231 676	246 815

ACINO | FINANCIAL REPORT
Segment results (condensed, unaudited)

in EUR 1 000	Peroral		Parenteral		Total	
	1.1.- 30.6.10	1.1.- 30.6.09	1.1.- 30.6.10	1.1.- 30.6.09	1.1.- 30.6.10	1.1.- 30.6.09
Total revenue (third party)	42 086	57 005	19 484	16 645	61 570	73 650
Costs of goods sold	(38 005)	(36 971)	(13 347)	(10 519)	(51 352)	(47 490)
Contribution margin	4 081	20 034	6 137	6 126	10 218	26 160

Transfer to net (loss) / profit before tax

Not contained in the Contribution margin per segment:

Work performed by the entity and capitalized	1 793	2 025
Employee benefits	(9 169)	(8 421)
Other operating expenses	(7 198)	(5 935)
Other operating income	265	140
Depreciation and amortization	(1 512)	(977)
Net financial result	1 307	1 261
Result from associated companies	669	354
Net (loss) / profit before tax	(3 627)	14 607

The definition and presentation of operating segments has not been changed compared with the annual report 2009.

ACINO | FINANCIAL REPORT
Quarterly Review (unaudited)

in EUR 1 000	2009					2010		
	Q1	Q2	Q3	Q4	Total	Q1	Q2	Total
Net revenues	37 778	35 872	43 895	40 638	158 183	35 729	25 841	61 570
Change in inventories	(1 080)	619	(67)	(380)	(908)	(722)	144	(578)
Work performed by the entity and capitalized	1 050	975	1 042	743	3 810	961	832	1 793
Goods and services purchased	(13 852)	(12 263)	(13 698)	(13 421)	(53 234)	(13 413)	(13 927)	(27 340)
Employee benefits	(7 535)	(7 844)	(7 801)	(7 804)	(30 984)	(8 250)	(8 581)	(16 831)
Other operating expenses	(4 462)	(5 024)	(5 813)	(6 638)	(21 937)	(5 588)	(5 880)	(11 468)
Other operating income	95	45	1 047	8 688	9 875	216	49	265
Operating profit / (loss) before depreciation, amortization, net financial result and taxes; EBITDA	11 994	12 380	18 605	21 826	64 805	8 933	(1 522)	7 411
Depreciation	(1 340)	(1 354)	(1 527)	(1 929)	(6 150)	(1 797)	(1 779)	3 576
Operating profit / (loss) before amortization, net financial result and taxes ; EBITDA	10 654	11 026	17 078	19 897	58 655	7 136	(3 301)	3 835
Amortization	(4 340)	(4 348)	(4 963)	(4 589)	(18 240)	(4 616)	(4 822)	(9 438)
Operating profit / (loss); EBIT	6 314	6 678	12 115	15 308	40 415	2 520	(8 123)	(5 603)
Financial income	1 039	222	(85)	(532)	644	793	514	1 307
Result from associated companies	222	132	178	269	801	630	39	669
Net profit / (loss) before tax	7 575	7 032	12 208	15 045	41 860	3 943	(7 570)	(3 627)
Income tax	(1 804)	(1 502)	(2 935)	(2 094)	(8 335)	(1 168)	2 065	897
Net profit / (loss)	5 771	5 530	9 273	12 951	33 525	2 775	(5 505)	(2 730)

Notes to the consolidated Half-year Report (unaudited)

▶ General information

The accounting principles of the consolidated Half-year Report correspond, unless stated otherwise, to the principles applied in the preparation of the financial statements of the Annual Report 2009 and are consistent with the International Financial Reporting Standards (IFRS).

On January 1, 2010 the International Accounting Standard Board (IASB) implemented several International Financial Reporting Standards (IFRS) and revised the existing International Accounting Standards (IAS) (the "IASB Improvement Project"). Numerous new standards, revisions and interpretations of existing standards were released, which must be applied for accounting periods commencing on January 1, 2010 or later. Unless otherwise stated, Acino Group does not apply them prematurely.

The consolidated interim financial statements are prepared in accordance with the International Accounting Standard 34 (IAS 34, Interim Financial Reporting).

In 2008 the Group already adopted the revised versions of IFRS 3 (Business Combinations) and IAS 27 (Consolidated and separate financial statements), which are required to be implemented from 1 January 2010 at the latest.

In 2010 the Group has implemented various amendments to existing standards and interpretations, which have no material impact on the Group's overall results and financial position.

The Group is currently assessing the potential impacts of the other new and revised standards and interpretations that will be effective from 1 January 2011 and beyond, and which the Group has not

early adopted. The Group does not anticipate that these will have a material impact on the Group's overall results and financial position.

Since January 1, 2010 the functional currency for all group companies located in Switzerland has been changed from CHF to EUR, as the majority of costs and revenues are denominated in this currency. Accordingly, with retrospective effect the reporting currency has been changed to EUR as of January 1, 2009.

▶ Changes in contingent liabilities and -assets

In connection with the recall of certain batches of clopidogrel claims could arise from customers against Acino, the satisfaction of which may not be fully covered by provisions made on the balance sheet or the provisions made could prove to be in excess of any potential claim. As of now, the Group has not recorded any receivables in its balance sheet for claims by Acino against insurers and suppliers in connection with the above-mentioned recall due to the inherent uncertainties.

▶ Seasonality

The activities of the Group are not subject to regular seasonal effects; however, new product introductions as well as price changes by marketing partners have a substantial impact on revenue amounts and margins.

▶ Share capital / treasury shares

The share capital of the Acino Holding Ltd. as of June 30, 2010 amounted to EUR 0.8 million (as of December 31, 2009 EUR 0.8 million), consisting of 3 192 000 (as of December 31, 2009: 3 192 000) registered, par value CHF 0.40, shares.

As of June 30, 2010, the Company directly, or indirectly through consolidated subsidiaries, held 18 227 of its own registered shares, par value CHF 0.40, (as of December 31, 2008: 27 044)

▶ Dividends paid

The General Meeting of Shareholders of March 30, 2010, approved the distribution of a gross dividend of CHF 2.50 per registered share. The payment occurred on April 8, 2010.

▶ Events after the balance sheet date

There were no events after the balance sheet date, which are required to be disclosed in this note.

ACINO | FIRST HALF-YEAR 2010 AT A GLANCE
Listing & Ticker symbols

Listing	SIX Swiss Exchange
Index membership	SPI
Telekurs / Bloomberg	ACIN
Reuters	ACIN.S
Securities number	2119090
ISIN number	CH0021190902

Market data

Share price as of 31.12.2009	CHF 161.00
Share price as of 30.6.2010	CHF 103.70
High first half-year 2010	CHF 185.80
Low first half-year 2010	CHF 102.00
1-year performance (Jan 10 - Jun 10)	(34%)
3-year performance (Jan 08 – Jun 10)	(34%)
5-year performance (Jan 06 – Jun 10)	(4%)

Contact

Peter Burema
 CEO Acino Group
 Phone +41 61 338 60 00
 info@acino-pharma.com
 www.acino-pharma.com

Calendar

28.10.10	Nine-month Figures as of 30.9.10
3.3.11	Annual Report 2010
3.3.11	Media & analyst conference
1.4.11	General Meeting of Shareholders


Acino – a focused pharmaceutical company

Acino specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration to sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in Basle (Switzerland), currently employs approximately 430 staff and generated annual revenues of about EUR 160 million in 2009. Acino Holding Ltd., the Group's parent, is listed on the SIX Swiss Exchange (SIX: ACIN).

Acino to discuss its Half-Year Report 2010

Acino invites members of the financial community to participate in an investor conference call.

Financial Community Conference Call on July 29, 2010 at 10:00 CEST / 09:00 BST

Acino will discuss its half-year results in a telephone conference with financial analysts and investors. Peter Burera (CEO) and Marcel von Ah (CFO) will summarize the results and will answer questions from the financial community. Conference language is English.

Participants, who will be asked for their name and company, are kindly requested to dial one of the following numbers approximately 10-15 minutes prior to the start of the call:

Dial-in numbers for live conference call

+41 (0)91 610 56 00 (Continental Europe)

+44 (0)207 107 06 11 (UK)

A playback of the conference will be available one hour after the end of the call for 24 hours. Interested parties wishing to listen to the digital playback please dial:

Phone numbers to access playback

+41 (0)91 612 43 30 (Continental Europe)

+44 (0)207 108 62 33 (UK)

+1 866 416 25 58 (USA - toll-free)

(when prompted please enter the Code 17959 followed by the # sign)